Novo’s Low-Cost Wegovy Offers Alternative To Compounders For Self-Pay Crowd
Five Doses Available At $499 Per Month
Novo is making Wegovy available through a new direct-to-patient delivery option for individuals paying out of pocket for the obesity drug as the potential end of semaglutide compounding nears.
